Sun Pharma Advanced Research Company Ltd Q2FY26 – ₹7.86 Cr Sales, ₹76 Cr Loss, -414% OPM: India’s Only Listed R&D House or a Perpetual Science Experiment?

1. At a Glance

Welcome to the strange little world of Sun Pharma Advanced Research Company Ltd (SPARC) — the country’s first listed pure-play pharmaceutical R&D firm that seems to believe profitability is just an optional elective. With a market cap of ₹4,252 crore and a share price of ₹131 (as of Nov 13, 2025), SPARC continues to be India’s most sophisticated money-incineration machine.

The company posted Q2FY26 revenue of ₹7.86 crore, down 39% YoY, and a net loss of ₹76 crore — roughly ₹83 lakh lost every single day this quarter. Its Operating Profit Margin (OPM) is a chilling -414%, and Return on Capital Employed (ROCE) is a mind-bending -298%. If accounting were a horror movie, this would be the jump-scare moment.

Promoters, led by Dilip Shanghvi (of Sun Pharma fame), still hold 65.7%, proving that conviction sometimes looks a lot like stubbornness. The company’s R&D expenses are gigantic compared to its tiny revenue — because in SPARC’s world, “future potential” is the only currency that matters.

2. Introduction

SPARC was spun out of Sun Pharmaceutical Industries Ltd in 2007 to independently focus on drug discovery, innovation, and technology platforms. Over the years, it’s become the kind of company that investors watch not for quarterly numbers, but for the possibility of a scientific miracle.

It’s not a regular pharma stock; it’s more like a pharmaceutical startup trapped in a listed company’s body. Its revenues come from licensing and royalty fees — and sometimes those cheques don’t arrive on schedule.

Unlike typical drug manufacturers who churn out branded generics and mint cash, SPARC burns it — investing hundreds of crores every year in long-gestation R&D projects. The company’s idea of success isn’t immediate profit; it’s a press release that says, “Phase 2 data readout expected next quarter.”

Investors here are not chasing dividends. They’re chasing dopamine. The stock is down 34% in one year, 19% in three years, and 4.8% in five — a steady reminder that drug discovery is not for the faint-hearted or the impatient.

So what exactly is SPARC trying to cure — diseases, or investor optimism? Let’s find out.

3. Business Model – WTF Do They Even Do?

SPARC doesn’t manufacture drugs. It discovers them, tests them, and (if it survives long enough) licenses them out to Big Pharma partners who take them through commercialization.

Think of it as the “Idea Guy” of the pharmaceutical world — it does the early-stage hard work, then lets someone else make the money.

Its revenue model has two key parts:

1. License Fees / Royalties – for drugs it develops and licenses to other companies.
2. R&D Services – working with partners like Visiox Pharma, Johns Hopkins University, and others.

In FY23, the company got USFDA approval for Sezaby (phenobarbital sodium injection) and licensed it out. It’s also developing several novel chemical entities (NCEs) like Vodobatinib, SCD-153, and SBO-154, targeting neurological, autoimmune, and oncology disorders.

SPARC employs 350+ scientists across 4 research facilities in Gujarat and Maharashtra. It has poured in ₹840 crore into R&D over FY22 and FY23. And yet, it barely makes enough revenue to pay for a small clinical trial’s snacks.

If pharma R&D were cricket, SPARC is the nightwatchman — sent in to survive, not score.

4. Financials Overview

Commentary:
Even by SPARC standards, this quarter was a masterclass in losing less money than before — a small victory in a company where “less negative” is the new positive. The loss narrowed 29% YoY, but that’s like saying a ship sank slower this time.

At